Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Tafamidis / Tafamidis Meglumin

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Iron(Iii) Sodium D-Gluconate Complex

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Substance Fondaparinux (Atc Code According to Who: B01ax05)

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Epoetin Zeta (Recombinant Human Erythropoietin)

Open House Biologics Rebate Contracts 2023-07 - Pegvisomant

Dynamic Purchasing System for Diagnostic Ultrasound.